Compass Pathways Surges as BTIG Reaffirms Buy Rating and Trump’s Psychedelic Executive Order Sparks Sector Rally

BTIG raises CMPS to Buy, $14 target; stock jumps 42% after Trump boosts psychedelic research funding and faster FDA paths.